Glutathione: The Body's Master Antioxidant, a Poorly-Absorbed Supplement

Summary

Glutathione is genuinely the body's central intracellular antioxidant, and raising it matters in one specific medical setting — paracetamol overdose, where the cysteine precursor NAC restores hepatic glutathione and saves lives — yet the consumer supplement built on that biology is oversold: oral glutathione is largely broken down in the gut so systemic absorption has long been considered near-zero (a single industry-funded trial showed modest rises in tissue stores, not any clinical outcome), the skin-whitening, "detox," anti-aging and fatty-liver claims rest on small, short, often industry-l

Why Emerging

Emerging Evidence because the entry's load-bearing verdict is about the supplement, and the supplement's marketed benefits sit at Emerging or below. The consumer claims — oral capsules for detox/energy, liposomal for anti-aging, IV for whitening — rest on small, short, heterogeneous, often industry-linked trials on surrogate endpoints, or on no efficacy trials at all (IV). That is the tier the entry inherits.

NOT Foundational or Strong for the product because the therapeutic anchors of the supplement are weak: the one positive oral-absorption RCT is single, industry-funded, and surrogate-only; the skin and fatty-liver data are low-quality; and the IV route has a safety warning with zero efficacy evidence.

Two parts are firmer than the headline tier, and are marked as such:
• Oral glutathione is poorly absorbed (near-zero historically; modest surrogate rises at best): Strong mechanism, independent and against seller interest.
• NAC — not glutathione — is the evidence-based route to raise glutathione, and the paracetamol-overdose antidote: Strong, but for NAC, deferred to nac_n_acetyl_cysteine; it does not lift the glutathione-product verdict.

The entry marks those explicitly rather than letting the real biology inflate the product's tier — which is exactly the conflation the marketing exploits.

Practical takeaway

The framing to hold: glutathione is a real, central endogenous antioxidant, but the consumer supplement is oversold. If you are a healthy person buying oral capsules, liposomal drops, or an IV drip for energy, detox, anti-aging or whiter skin, you are paying for a poorly-absorbed supplement (or an unregulated injection) whose marketed benefits are unproven. If you genuinely need to raise glutathione for a real indication, the evidence-based route is NAC — under clinical guidance — not glutathione itself.

Don't buy it for the mass-market reasons.
• Energy / anti-aging / "master antioxidant" in a healthy person: skip it. No trial shows a clinically meaningful benefit from raising glutathione by supplementation in healthy, non-deficient people, and oral absorption is poor.
• "Detox" / fatty liver: skip it. It is not in NAFLD guidelines; the proven lever for fatty liver is 7-10% weight loss (see liver_health_nafld). Do not let a supplement substitute for that or delay seeking care.
• Skin whitening (oral or IV): the oral evidence is low-quality and the IV route carries a regulatory safety warning. This is not a self-directed use; for pigmentation concerns see melasma_and_hyperpigmentation and a clinician.

If glutathione status genuinely matters, use the right tool.
• Paracetamol overdose is a medical emergency treated with NAC in hospital — never a DIY glutathione product. If overdose is suspected, seek emergency care immediately.
• To raise glutathione supportively, the cysteine precursor NAC is the evidence-based, better-absorbed route; discuss it with a clinician rather than reaching for oral or IV glutathione (see nac_n_acetyl_cysteine).

Know the honest ceiling. Outside supervised clinical settings, the expected benefit of a glutathione product is essentially unproven, oral absorption is poor, and the IV route swaps an unproven benefit for a genuine safety risk. The molecule is real; the shelf product and the drip are the part to be skeptical of.

Evidence detail

Why This Entry Exists

Glutathione is the textbook example of a supplement where the biochemistry is real and the product is a stretch, and the marketing deliberately fuses the two. "Master antioxidant" is not a lie — glutathione is the most abundant intracellular thiol antioxidant, it buffers cellular redox, it is a cofactor for the glutathione-S-transferase detoxification enzymes, and it recycles vitamins C and E. That real biology is then bolted onto a shelf product or an IV drip and sold as an energy, detox, anti-aging and skin-whitening cure. The gap between "central molecule in your cells" and "swallowing or injecting it does something useful in a healthy person" is where this entry lives.

The entry has to do two opposite jobs at once. It must defend the genuine biology and the one Tier-1 clinical indication (NAC restoring glutathione in paracetamol overdose) against a lazy "supplements are all snake oil" dismissal, and it must dismantle the mass-market pitch that the same word — glutathione — is used to sell. Getting the ordering right matters: the endogenous antioxidant role is real, the overdose indication is real (via NAC, medically supervised), and everything the consumer is actually being sold — oral capsules for detox, liposomal for anti-aging, IV drips for whiter skin — is Emerging-at-best or carries a safety warning.

What bad advice this protects against, in all directions:
• "Glutathione is the master antioxidant — everyone should supplement it" → the descriptor is real biochemistry, but no trial shows that raising glutathione by supplementation produces a clinically meaningful benefit in healthy people; endogenous adequacy is the norm, and antioxidant-supplement history counsels against assuming "more antioxidant = better."
• "Take oral glutathione to boost your levels" → the tripeptide is largely hydrolysed in the gut before absorption, so systemic bioavailability has long been considered near-zero; the one trial showing modest body-store rises measured surrogate tissue stores, not any clinical outcome, and it was funded by the ingredient maker.
• "Glutathione whitens skin / reverses aging" → the evidence is small, short, heterogeneous RCTs rated low-quality; efficacy is questionable and sustainability unclear (defer skin detail to melasma_and_hyperpigmentation).
• "A gluta IV drip detoxes and brightens you" → IV glutathione for skin-whitening is unregulated, has no efficacy trials, and carries a named regulatory safety warning (hepatic, renal, neurological toxicity and Stevens-Johnson Syndrome).
• "Glutathione reverses fatty liver / detoxes you" → not in NAFLD guidelines; supportive data are tiny uncontrolled pilots on surrogate markers, and the proven lever for fatty liver is 7-10% weight loss (defer to liver_health_nafld).
• "Glutathione is useless, skip it entirely" → the reverse over-correction; the endogenous molecule is central and the overdose indication (via NAC) is life-saving. The problem is the product, not the molecule.
• "If I want more glutathione, glutathione is the way to get it" → the evidence-based route to raise glutathione for a real indication is NAC, which supplies the rate-limiting cysteine — not swallowing or injecting glutathione (defer to nac_n_acetyl_cysteine).

This entry owns the glutathione-supplement verdict (oral / liposomal / IV) and the "master antioxidant" pitch. It defers the cysteine-precursor pharmacology and the paracetamol-overdose indication to nac_n_acetyl_cysteine, the skin-lightening detail to melasma_and_hyperpigmentation, and fatty-liver management to liver_health_nafld. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by claim, with the tier signal inline. The endogenous biology and the poor-absorption reality are the firmest parts; the marketed consumer benefits are Emerging-at-best; the IV route carries a safety signal, not an efficacy one. Read the tiers, not just the thesis.

The biology is real, and the one clinical route runs through NAC (Strong, but not for the glutathione product).

1. The legitimate, evidence-based way to raise glutathione for a real indication is NAC (N-acetylcysteine), not glutathione itself. NAC supplies the rate-limiting cysteine and replenishes hepatic glutathione, and it is the standard antidote in paracetamol/acetaminophen overdose (nomogram-guided, medically supervised). This is the Strong-Evidence receipt that makes glutathione biology matter clinically — and it does not validate glutathione-the-supplement, because the effective agent is the precursor, given in hospital, for a specific poisoning. (Established clinical pharmacology/toxicology: NAC as the acetaminophen-overdose antidote. Full detail deferred to nac_n_acetyl_cysteine. Strong Evidence for the indication — decades of clinical use — but it is Strong for NAC, not for oral/IV glutathione products. Tellingly, NAC is generic and off-patent, so no one markets it hard, which is itself informative about why glutathione — brandable — is pushed harder than the evidence supports.)

Oral glutathione is poorly absorbed — the firm skeptical finding (Strong mechanism, against seller interest).

2. Oral glutathione has long been considered to have near-zero systemic bioavailability. The tripeptide is hydrolysed in the gut by intestinal gamma-glutamyltransferase (GGT) into its constituent amino acids before absorption, so dietary or oral glutathione is not a major determinant of systemic glutathione levels; reviews put bioavailability below about 1% and conclude that the clinical efficacy of oral glutathione is questionable given the limited absorption. This is the mechanistic backbone of the skeptical read on the whole oral-supplement category. (Narrative and systematic reviews on glutathione supplementation — e.g. Sonthalia et al., Indian J Dermatol Venereol Leprol 2016; 2025 narrative review, PMC11862975. Strong mechanism — well-established gut hydrolysis. The direction runs AGAINST industry interest, which strengthens it: independent/academic reviews with no seller stake.)

The one positive absorption trial is the ingredient maker's, and it measured stores, not outcomes (Emerging, industry-funded).

3. The strongest pro-supplement data — a 6-month RCT — showed oral glutathione modestly raised measured body stores, but no clinical outcome. In 54 non-smoking adults, oral glutathione at 250 or 1000 mg/day raised body stores versus placebo: roughly 30-35% in erythrocytes, plasma and lymphocytes, and about 260% in buccal cells at the high dose. This is the "some newer data suggest modest body-store rises" caveat that softens the older "near-zero, pointless" line — but it is a surrogate endpoint (tissue stores), not any health outcome, from a single trial. (Richie JP et al., "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione," Eur J Nutr 2015;54(2):251-263, DOI 10.1007/s00394-014-0706-z, n=54. Emerging — surrogate endpoint, no clinical outcome, single trial. INDUSTRY: funded/supplied by Kyowa Hakko Bio's branded Setria glutathione and showcased on setriaglutathione.com; a published commentary, PMID 25792077, flags interpretive caveats. Classic cui bono — the one positive absorption RCT is the ingredient maker's.)

Skin-whitening: small, short, low-quality trials (Emerging-to-Experimental).

4. Oral glutathione for skin whitening rests on a handful of small, short RCTs, and systematic review rates the overall evidence low-quality. The trials are typically tens of participants over a few weeks measuring a surrogate melanin index (e.g. a ~500 mg/day, n=60, 4-week trial in Thai students using Mexameter readings). Systematic review concludes efficacy is questionable and the overall body of evidence is low-quality, limited by few studies, heterogeneous methods and outcomes, and variable durability of any effect. (Systematic/narrative reviews of glutathione for skin lightening — PMC11862975, 2025; IJDVL 2016; plus an oral-glutathione skin-appearance RCT, Weschawalit et al. Reviews: "overall low quality of evidence." Emerging-to-Experimental for the skin-whitening claim — small/short RCTs, surrogate melanin-index endpoints. Skin-lightening is a large consumer market and several trials sit in that commercial context. Defer skin detail to melasma_and_hyperpigmentation.)

IV glutathione for whitening: a named regulatory safety warning, no efficacy trials (safety signal + no evidence).

5. IV glutathione for skin whitening is unregulated and carries a genuine safety signal. The Philippine FDA (Advisory No. 2019-182) warns that injectable glutathione is NOT approved for skin lightening — it is approved only as an adjunct in cisplatin chemotherapy — and cites risks including hepatic, renal and nervous-system toxicity and Stevens-Johnson Syndrome / toxic epidermal necrolysis. There are no human efficacy trials for the whitening use and no established dosing or duration. (Philippine FDA Advisory No. 2019-182, "Unsafe Use of Glutathione as Skin Lightening Agent"; DOH warnings, 2023; review PMC5808366, "Glutathione for skin lightening: a regnant myth or evidence-based verity?" A named regulatory safety warning plus no-evidence-for-efficacy. IV "gluta drip" clinics are direct-pay wellness businesses with no reimbursement gatekeeping and a strong incentive to oversell; the regulator sits on the consumer-protection side.)

"Detox" and fatty-liver: uncontrolled pilots on surrogates, absent from guidelines (Emerging-to-Experimental).

6. The "detox" and fatty-liver claims are unproven and not in guidelines. Oral glutathione is not recommended in NAFLD guidance — it is absent from APASL clinical practice guidelines, NICE does not recommend it, and it is not NHS standard care. The supportive data are tiny open-label / single-arm pilots (on the order of a few small studies, roughly a hundred participants total) reporting only surrogate changes such as ALT or the oxidative-stress marker 8-OHdG. The proven lever for fatty liver is 7-10% weight loss. (Honda et al., open-label single-arm NAFLD pilot, BMC Gastroenterol 2017, PMC5549431; literature review PMC11940638; a 2024 fact-check on the "oral glutathione reverses fatty liver" claim; NICE NG49 for the weight-loss lever. Emerging-to-Experimental — surrogate endpoints, uncontrolled pilots, absent from guidelines. "Detox" is a marketing frame widely flagged as vague and non-clinical. Defer to liver_health_nafld.)

"Master antioxidant" is real biochemistry used as a marketing hook (Emerging as a supplement benefit).

7. "Master antioxidant" describes real biochemistry but is used as a supplement-marketing hook. Glutathione genuinely is the most abundant intracellular thiol antioxidant and it recycles vitamins C and E — that descriptor is textbook. But no trial shows that raising glutathione via supplementation produces a clinically meaningful benefit in healthy people; endogenous adequacy in healthy adults is the norm, and the broader history of antioxidant supplements (the high-dose vitamin E prostate-cancer signal in SELECT, the beta-carotene harm signals) counsels against assuming "more antioxidant = better." (General antioxidant-supplement literature; the descriptor's biochemical basis is textbook, the healthy-population benefit claim is unsupported by outcome trials. Emerging — mechanistically real, clinically unproven as a supplement benefit. The phrase is near-ubiquitous in seller copy — supplement blogs, IV clinics — and benefits sellers rather than being demonstrated by trials.)

Mechanism

This entry owns the supplement verdict and the absorption reality, not the full cysteine-precursor pharmacology, which is deferred to nac_n_acetyl_cysteine. What follows is only enough mechanism to make the pitch and its ceiling intelligible.

Why "master antioxidant" is biochemically real. Glutathione (a glutamate-cysteine-glycine tripeptide) is the most abundant intracellular thiol antioxidant. It buffers cellular redox state, serves as the cofactor for glutathione-S-transferase and glutathione-peroxidase enzymes (the real basis of the "detoxification" association), and regenerates the oxidised forms of vitamins C and E. This is the sliver of genuine biology the marketing rests on, and it is why dismissing glutathione as "nothing" is wrong — the molecule is central.

Why swallowing it does little. Glutathione is a tripeptide, and the gut treats tripeptides the way it treats protein — it breaks them down. Intestinal gamma-glutamyltransferase hydrolyses oral glutathione into its constituent amino acids before absorption, so very little intact glutathione reaches the circulation, and systemic levels are governed by endogenous synthesis, not by what you swallow. This is why oral bioavailability has long been considered near-zero, and why the "boost your glutathione with a capsule" pitch is mechanistically weak. The Richie trial's modest rise in tissue stores is best read as the amino-acid building blocks feeding endogenous synthesis, not as intact glutathione surviving the gut — and it is a surrogate, not a demonstrated health effect.

Why the precursor route works where the product does not. The rate-limiting step in making glutathione is the availability of cysteine. NAC delivers cysteine efficiently, so it raises hepatic glutathione — which is exactly why NAC, not glutathione, is the antidote that restores glutathione in paracetamol overdose. The mechanism that makes glutathione clinically matter is therefore a mechanism that argues for the precursor and against the product.

Why the IV route is a safety story, not an efficacy one. Injecting glutathione bypasses the gut and does raise blood levels, which is why clinics sell it — but "raises a blood level" is not "produces a clinical benefit," there are no outcome trials for the whitening use, and the compounded, unregulated products carry documented toxicity (hepatic, renal, neurological) and severe cutaneous reactions (Stevens-Johnson Syndrome). The mechanism here caps the claim: even where absorption is not the barrier, demonstrated benefit is still absent and the risk is real.

Risks And Contraindications

• IV glutathione for skin whitening carries a named regulatory safety warning — this is the load-bearing safety item. The Philippine FDA (Advisory 2019-182) warns injectable glutathione is not approved for lightening and cites hepatic, renal and nervous-system toxicity and Stevens-Johnson Syndrome / toxic epidermal necrolysis. Add compounded-product contamination risk in an unregulated direct-pay market, and a theoretical long-term concern that suppressing melanin could raise UV and skin-cancer risk. Do NOT treat a "gluta drip" as a benign cosmetic procedure.
• Opportunity cost and false reassurance. "Detox" and fatty-liver marketing can divert people from the proven lever (7-10% weight loss for NAFLD — see liver_health_nafld) or from seeking care. The entry must never imply oral or IV glutathione is a validated way to "boost immunity," "detox," or reverse liver disease.
• Money on a poorly-absorbed product. For oral glutathione the realistic harm in a healthy person is spending on a supplement that is largely broken down in the gut, plus the false confidence of "doing something."
• Keep the NAC-in-overdose fact walled as clinical. NAC restoring glutathione in paracetamol overdose is a medically supervised hospital treatment, not a DIY endorsement of any glutathione product. Suspected overdose is an emergency — seek care, do not self-treat.
• Don't let the real biology launder the product. The molecule being a central endogenous antioxidant does not make the capsule, the liposomal drops, or the IV drip a demonstrated benefit. Guard against the "it's the master antioxidant, so supplementing it must help" leap in either the copy or the coaching.
• Avoid the opposite over-correction. "Glutathione is useless" is also wrong: the endogenous molecule is central and the overdose indication (via NAC) is life-saving. The honest message is "real molecule, oversold product," not a blanket dismissal.

Controversy

Nature: a genuinely central endogenous antioxidant wrapped in a mass-market pitch — energy, detox, anti-aging, skin-whitening — that the evidence does not support, with error possible at both poles: over-claiming the supplement on one side, and dismissing the real biology and the NAC-in-overdose indication on the other.

Position A — "Glutathione is the body's central antioxidant and raising it matters." The real-biology take.
• Best evidence: glutathione is the most abundant intracellular thiol antioxidant, a cofactor for detoxification enzymes, and a redox buffer; and NAC — which raises hepatic glutathione by supplying cysteine — is the life-saving antidote in paracetamol overdose. Newer RCT data (Richie 2015) show sustained oral dosing can modestly raise measured body stores, so the old "near-zero bioavailability, pointless" line is now too strong.
• Where it goes wrong if overstated: it slides from "the molecule matters" to "so the supplement works," treats a surrogate rise in tissue stores as a health outcome, and lets the overdose indication (which is really about NAC) validate oral capsules and IV drips.

Position B — "The consumer supplement is oversold." The debunk take.
• Best evidence: oral glutathione is largely hydrolysed in the gut (bioavailability historically below ~1%); the skin-whitening, anti-aging, detox and fatty-liver claims rest on small, short, heterogeneous, often industry-linked studies rated low-quality; IV drips are an unregulated direct-pay market with no outcome trials and a real safety signal (regulatory warnings, Stevens-Johnson Syndrome, hepato/renal/neuro toxicity). "Master antioxidant" is a marketing frame, not a demonstrated benefit in healthy people.
• Where it goes wrong if overstated: it can tip into "glutathione is useless," ignoring the central endogenous role and the genuine NAC-in-overdose indication.

The funding/bias dimension — cui bono, both ways. Toward over-claiming: the pro-supplement side carries nearly all the commercial pressure. The single positive oral-absorption RCT (Richie 2015) was funded/supplied by Kyowa Hakko Bio and showcases its branded Setria glutathione; newer "enhanced bioavailability" formulations (liposomal, LipoMicel) surface via trade press and ingredient-maker studies; IV "gluta drip" clinics are direct-pay businesses with no reimbursement gatekeeping and every incentive to oversell the "detox / whitening" frames. Toward the corrective pole: cui bono the other way is weak — the skeptical evidence comes from independent reviews and regulators (Philippine FDA/DOH, NICE, APASL guidelines) whose incentives run toward consumer protection, and the reverse tell is loud: NAC, the actually evidence-based route to raise glutathione, is generic and off-patent, so no one markets it, which partly explains why glutathione itself is pushed harder than the evidence supports.

Realised Position: Both are true and must be held together. The endogenous biology is genuinely central and the NAC-in-overdose indication is Strong (defer detail to nac_n_acetyl_cysteine). But for a healthy person buying it off a shelf or at an IV clinic, the marketed benefits are unproven: oral absorption is poor (the exceptions are industry-funded and measure surrogate stores, not outcomes), the skin / detox / anti-aging / liver claims are Emerging-at-best, and IV drips carry a genuine safety warning with zero efficacy evidence. If the goal is to raise glutathione for a real indication, NAC — not glutathione itself — is the evidence-based route.

Cross-Pillar Connections

Glutathione is a diet/supplement topic with a skin-pigmentation tail and a liver tail, so its connections span the supplement-literacy, dermatology and hepatic lines.
• Supplements (nac_n_acetyl_cysteine): owns the cysteine-precursor pharmacology and the paracetamol-overdose antidote; this entry holds only that NAC — not glutathione — is the evidence-based route to raise glutathione, and defers the detail there.
• Conditions / skin (melasma_and_hyperpigmentation): owns pigmentation management; this entry holds only that oral glutathione whitening is low-quality evidence and IV whitening carries a safety warning, and defers skin-lightening there.
• Conditions / liver (liver_health_nafld): owns fatty-liver management and the 7-10% weight-loss lever; this entry holds only that glutathione is not in NAFLD guidelines and defers management there.
• Supplements (supplement_form_elemental_dose_and_bioavailability): the general absorption/bioavailability framework; this entry holds only the glutathione-specific reality (gut hydrolysis, near-zero oral bioavailability) and defers the general principle there.
• Foundations (publication_bias_and_evidence_distortion): the mechanism behind the single-sponsored-trial and selective-citation pattern that inflates glutathione's apparent evidence.
• Supplements (universal_nearuniversal_supplementation): the reference point for which supplements clear the bar for near-universal use — glutathione conspicuously does not, which is the contrast this entry draws.

What would change our mind

Industry bias note

Sources (8)

• Sonthalia S, et al. (2016). Glutathione for skin lightening / supplementation review. Indian J Dermatol Venereol Leprol; with a 2025 narrative review, PMC11862975. (Independent/academic; skeptical direction runs against industry interest.) — oral glutathione largely hydrolysed by intestinal gamma-glutamyltransferase before absorption; bioavailability below ~1%; clinical efficacy of oral glutathione questionable given limited absorption.↗
• Richie JP, et al. (2015). "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione." Eur J Nutr 54(2):251-263, DOI 10.1007/s00394-014-0706-z.↗ (INDUSTRY: funded/supplied by Kyowa Hakko Bio; branded Setria glutathione; showcased on setriaglutathione.com; interpretive commentary at pubmed.ncbi.nlm.nih.gov/25792077↗/" target="_blank" rel="noopener">PMID 25792077↗.) — n=54 non-smoking adults; 250 or 1000 mg/day for 6 months raised body stores (~30-35% erythrocytes/plasma/lymphocytes; ~260% buccal cells at high dose) versus placebo. Surrogate endpoint (tissue stores), no clinical outcome.
• Weschawalit S, et al. Oral glutathione and skin appearance RCT; with systematic/narrative reviews of glutathione for skin lightening, PMC11862975 (2025) and IJDVL 2016. (Skin-lightening consumer market context.) — small, short RCTs on surrogate melanin index; reviews conclude "overall low quality of evidence" and questionable efficacy.↗
• Philippine FDA Advisory No. 2019-182, "Unsafe Use of Glutathione as Skin Lightening Agent"; DOH warnings (2023); review PMC5808366, "Glutathione for skin lightening: a regnant myth or evidence-based verity?" (Regulator/consumer-protection side.) — injectable glutathione not approved for lightening (approved only as a cisplatin-chemotherapy adjunct); cited risks: hepatic, renal, nervous-system toxicity, Stevens-Johnson Syndrome / toxic epidermal necrolysis; no efficacy trials, no established dosing/duration.↗
• Honda Y, et al. (2017). Open-label single-arm NAFLD pilot. BMC Gastroenterol, PMC5549431; with literature review PMC11940638 and a 2024 fact-check of the "oral glutathione reverses fatty liver" claim; NICE NG49 for the weight-loss lever. (Academic/regulatory; "detox" is a non-clinical marketing frame.) — tiny uncontrolled pilots on surrogate ALT / 8-OHdG; oral glutathione absent from APASL/NICE/NHS guidance; proven NAFLD lever is 7-10% weight loss.↗
• Established clinical toxicology: NAC (N-acetylcysteine) as the paracetamol/acetaminophen-overdose antidote. (Off-patent generic; no seller push — itself informative.) — NAC supplies rate-limiting cysteine and replenishes hepatic glutathione; the evidence-based route to raise glutathione for a real indication. Detail deferred to nac_n_acetyl_cysteine.↗
• General antioxidant-supplement literature (e.g. the high-dose vitamin E SELECT signal; beta-carotene harm signals). (Cautionary background.) — "master antioxidant" is a real biochemical descriptor (most abundant intracellular thiol antioxidant; recycles vitamins C and E) but no outcome trial shows a benefit from raising glutathione by supplementation in healthy people; "more antioxidant = better" is not a safe assumption.↗
• Funding notation: the load-bearing counter-claims (poor oral absorption; low-quality skin/liver data; the IV safety warning) come from independent reviews and regulators with no seller interest, and NAC's off-patent status means the actually-evidence-based route is un-marketed — so those claims are trustworthy. The most commercially-motivated claims (the single industry-funded absorption RCT, the "enhanced bioavailability" liposomal upsell, and the IV "detox/whitening" drip) are exactly the ones the entry marks and hedges. The bias vector runs almost entirely toward over-claiming benefit.*↗

Related entries